Prenetics completes $70 million sale of Insighta stake to Tencent

Global genomics company Prenetics completed a $70 million sale of its Insighta stake to Chinese tech giant Tencent in a strategic transaction that expands Tencent's presence in the digital health sector while providing Prenetics with additional capital for expansion. The deal represents a significant move in the rapidly growing genomics and digital health market, where both companies have been establishing their presence. Prenetics, known for its COVID-19 testing solutions and broader genomics services, had developed Insighta as a digital health platform that integrates genetic testing with personalized health recommendations. By divesting this stake, Prenetics can focus on its core genomics testing business while securing substantial funding to accelerate research and development initiatives. Tencent's acquisition of the Insighta stake demonstrates the Chinese technology conglomerate's strategic expansion into healthcare technology, leveraging its extensive resources and digital ecosystem to enhance healthcare offerings in China and potentially expand internationally.